AIM: To assess the efficacy of dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) in prediction of the response to treatment in patients with head and neck cancers (HNCs). METHODS AND MATERIALS: Twenty-one patients with advanced HNC, suitable for concurrent chemoradiotherapy underwent DCE MRI, for the quantification of blood flow (BF) and volume (BV). All the patients received radical doses of conventionally fractionated radiotherapy up to a dose of 70 Gy along with concurrent weekly cisplatin. RESULTS: The values of BV and BF were higher in complete responders as compared to partial responders at primary as well as nodes. Both BF and BV were found to be significantly higher in patients with high T-stage as compared to patients with lower T-stage. CONCLUSIONS: DCE metrics can be used as a predictor of response to treatment in locally advanced HNCs after validation of these observations in a larger number of patients.
AIM: To assess the efficacy of dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) in prediction of the response to treatment in patients with head and neck cancers (HNCs). METHODS AND MATERIALS: Twenty-one patients with advanced HNC, suitable for concurrent chemoradiotherapy underwent DCE MRI, for the quantification of blood flow (BF) and volume (BV). All the patients received radical doses of conventionally fractionated radiotherapy up to a dose of 70 Gy along with concurrent weekly cisplatin. RESULTS: The values of BV and BF were higher in complete responders as compared to partial responders at primary as well as nodes. Both BF and BV were found to be significantly higher in patients with high T-stage as compared to patients with lower T-stage. CONCLUSIONS:DCE metrics can be used as a predictor of response to treatment in locally advanced HNCs after validation of these observations in a larger number of patients.
Authors: Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken Journal: Oncologist Date: 2017-05-22
Authors: N Fujima; D Yoshida; T Sakashita; A Homma; A Tsukahara; K K Tha; K Kudo; H Shirato Journal: AJNR Am J Neuroradiol Date: 2015-10-01 Impact factor: 3.825
Authors: Mischa de Ridder; Cornelis P J Raaijmakers; Frank A Pameijer; Remco de Bree; Floris C J Reinders; Patricia A H Doornaert; Chris H J Terhaard; Marielle E P Philippens Journal: Cancers (Basel) Date: 2022-06-20 Impact factor: 6.575
Authors: Ann D King; Steven Kwok Keung Chow; Kwok-Hung Yu; Frankie Kwok Fai Mo; David K W Yeung; Jing Yuan; Benjamin King Hong Law; Kunwar S Bhatia; Alexander C Vlantis; Anil T Ahuja Journal: PLoS One Date: 2015-12-10 Impact factor: 3.240
Authors: Christopher N Rumley; Mark T Lee; Lois Holloway; Robba Rai; Myo Min; Dion Forstner; Allan Fowler; Gary Liney Journal: BMC Cancer Date: 2017-07-10 Impact factor: 4.430
Authors: Madhava P Aryal; Choonik Lee; Peter G Hawkins; Christina Chapman; Avraham Eisbruch; Michelle Mierzwa; Yue Cao Journal: Tomography Date: 2019-03